Abstract
Objective To explore the effect and safety of paclitaxel combined with trastuzumab in the treatment of operability breast cancer patients with human epidermal growth factor receptor-2 positive.Methods 22 of special genetic marker,known as her2 positive invasive breast cancer patients to give the bead sheet music combined paclitaxel of every 3 new adjuvant chemotherapy treatment scheme,parallel radical surgery,and the clinical efficacy and side reactions were evaluated.Results 22 patients after treatment,13 cases complete remission,part of ease in 3cases,4 cases were stable,progress in 2 cases,the effective rate was 72.7％ ( 16/22 ),disease control rates for 90.9％(20/22) ; Richard completely ease 12 cases( 54.6％ ).Adverse reaction was mainly bone marrow inhibition and gastrointestinal reaction.Conclusion The bead sheet music combined paclitaxel of neoadjuvant chemotherapy treatment scheme special genetic marker,known as her2 positive can be the surgical treatment for breast cancer is better,and safe,has the high pathologic complete remission rate and efficient. Key words: Breast neoplasms; Receptor,epidermal growth factor; Paclitaxel; Trastuzumab
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
